Hepatitis/MASH

Combination therapy cuts standard HCV treatment regimen from 12 weeks to 8 weeks.

HEV is reemerging as a zoonotic virus, with individuals becoming infected via pigs and pork products.

The label has been updated to include data from adults co-infected with hepatitis C virus and HIV-1.

Top articles of the week from Specialty Pharmacy Times.

Prequalification will allow countries to access generic sofosbuvir and an HIV self-test.

Approximately 325 million individuals are living with hepatitis worldwide.

There are now 8 FDA approved medications for HCV treatment, all of which bypass the use of interferon.

Those who battled hepatitis C recount their journey to spread awareness on World Hepatitis Day.

World Hepatitis Day highlights awareness and prevention initiatives in effort to improve access to curative treatments.

World Hepatitis Day brings awareness to the burden of hepatitis, which is a leading cause of death worldwide.

Sci-B-Vac is a third-generation vaccine against hepatitis B virus.

New treatments for inflammatory conditions, cancer, and HIV are on the horizon. 

Top articles of the week from The American Journal of Pharmacy Benefits.

Transplanting organs from donors infected with hepatitis C found to be a viable option.

New generation of antiviral drugs cause significant reduction in the risk for the most common type of adult liver cancer in patients with HCV.

Outreach efforts seek to address rates of undiagnosed hepatitis C virus among homeless veterans.

Hepatitis C virus is a major cause of liver-related morbidity and mortality.

Vosevi is a fixed-dose, combination tablet containing sofosbuvir and velpatasvir, as well as the new drug voxilaprevir, according to a press release.

Latest hepatitis C treatment approved by FDA is a combination of containing sofosbuvir, velpatasvir, and voxilaprevir.

The combination tablet is approved to treat adults with hepatitis C genotypes 1-6 without cirrhosis or mild cirrhosis.

New cases of hepatitis C virus increased among young men by 55% in 2015.

Opioids have caused more than 70% of health events among patients with drug use disorder around the world.

Selective oral immunomodulator plus tenofovir alafenamide (Vemlidy) seeks functional cure in chronic HBV.

Top news of the day from across the health care landscape.

No data were presented for treatment-naïve and pretreated adolescents with hepatitis B virus.